Pacific Biosciences of California PACB Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's business segments — net loss?
- Pacific Biosciences of California (PACB) reported business segments — net loss of -$8.28M in Q1 2026.
- How has Pacific Biosciences of California's business segments — net loss changed year-over-year?
- Pacific Biosciences of California's business segments — net loss increased by 98.1% year-over-year, from -$426.08M to -$8.28M.
- What is the long-term trend for Pacific Biosciences of California's business segments — net loss?
- Over 3 years (2022 to 2025), Pacific Biosciences of California's business segments — net loss has grown at a 20.2% compound annual growth rate (CAGR), from -$314.25M to -$546.38M.
- What does business segments — net loss mean?
- This represents the bottom-line financial result for the reportable segment when operating expenses, taxes, and other charges exceed total revenues. It indicates the extent to which the segment is currently consuming capital rather than generating profit. Tracking this metric is critical for assessing the segment's path to profitability and its overall financial sustainability.